Abstract
Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Current Molecular Medicine
Title: Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Volume: 5 Issue: 8
Author(s): Lisa E. Hensley, Steven M. Jones, Heinz Feldmann, Peter B. Jahrling and Thomas W. Geisbert
Affiliation:
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Abstract: Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Export Options
About this article
Cite this article as:
Hensley E. Lisa, Jones M. Steven, Feldmann Heinz, Jahrling B. Peter and Geisbert W. Thomas, Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures, Current Molecular Medicine 2005; 5 (8) . https://dx.doi.org/10.2174/156652405774962344
DOI https://dx.doi.org/10.2174/156652405774962344 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry An Efficient Synthesis of 7,11-diarylspiro[5.5]undecane-1,9-dione by the Michael Condensation Under Ultrasound Irradiation in Aqueous and Organic Two Phase in the Presence of Phase-Transfer Catalyst
Letters in Organic Chemistry Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art
Current Drug Targets State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review
Current Neuropharmacology Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose
Current Pharmaceutical Design Toxicokinetic Interaction Between Quetiapine and Antiretroviral Therapy Following Quetiapine Overdose
Drug Metabolism Letters Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Development of Poly(lactide-co-glicolide) Nanoparticles Incorporating Morphine Hydrochloride to Prolong its Circulation in Blood
Current Pharmaceutical Design Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Current Pharmaceutical Biotechnology